Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole Effect on Ibrutinib PK in Healthy Adults
NCT02638116Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 7, Time to Reach Maximum Plasma Concentration at Day 7 and 2 more. Started Jan 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02638116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638116.